Neurocrine Biosciences Inc
NASDAQ: NBIX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
Neurocrine Biosciences Inc (NBIX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $389.68M | $276.65M | $118.18M | $70.82M | $144.42M | $138.37M | $195.98M | $154.68M | $243.03M | $474.79M | $365.09M | $817.59M | $993.15M | $1.31B | $1.73B | $2.07B | $2.37B | $3.25B | $3.72B | $4.63B |
| Cash & equivalents | $80.98M | $99.66M | $68.47M | $37.33M | $54.05M | $50.11M | $63.75M | $44.79M | $31.01M | $74.19M | $83.27M | $254.71M | $141.71M | $112.28M | $187.10M | $340.80M | $262.90M | $251.10M | $233.00M | $713.00M |
| Current assets | $193.66M | $182.95M | $81.42M | $55.39M | $133.05M | $132.48M | $189.26M | $148.46M | $198.20M | $384.07M | $310.44M | $554.92M | $737.78M | $831.00M | $1.02B | $972.80M | $1.45B | $1.61B | $1.72B | $2.52B |
| Total liabilities | $74.96M | $157.96M | $81.41M | $66.86M | $125.08M | $78.29M | $41.61M | $34.27M | $34.33M | $50.33M | $50.21M | $445.45M | $512.39M | $669.10M | $608.50M | $698.50M | $660.90M | $1.02B | $1.13B | $1.38B |
| Current liabilities | $20.12M | $29.91M | $26.09M | $19.96M | $52.78M | $47.11M | $15.65M | $11.70M | $15.66M | $25.71M | $30.41M | $54.43M | $88.23M | $565.30M | $186.50M | $245.80M | $537.70M | $654.80M | $507.70M | $743.40M |
| Long-term debt | $49.15M | $108.75M | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $369.62M | $388.50M | $408.81M | $317.90M | $335.10M | — | — | — | — |
| Shareholder equity | $314.72M | $118.70M | $36.77M | $3.95M | $19.34M | $60.08M | $154.37M | $120.41M | $208.70M | $424.45M | $314.88M | $372.14M | $480.76M | $636.90M | $1.13B | $1.37B | $1.71B | $2.23B | $2.59B | $3.25B |
| Retained earnings | $-407.35M | $-614.65M | $-703.26M | $-754.30M | $-762.27M | $-724.70M | $-719.67M | $-765.76M | $-826.30M | $-915.23M | $-1.06B | $-1.20B | $-1.18B | $-1.13B | $-725.40M | $-635.80M | $-406.80M | $-157.10M | $29.20M | $447.70M |
| Accounts receivable | $7.19M | $27000.00 | $39000.00 | — | $4.47M | $1.90M | $14.09M | $23000.00 | — | — | — | $31.13M | $56.24M | $126.58M | $157.10M | $185.50M | $350.00M | $439.30M | $479.10M | $686.80M |
| Inventory | — | — | — | — | — | $0.00 | $-14.09M | $-23000.00 | $0.00 | $0.00 | $0.00 | $-31.13M | $10.86M | $17.29M | $28.00M | $30.50M | $35.10M | $38.30M | $57.40M | $69.00M |
| Goodwill | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | $5.40M | $5.80M | $5.70M | — |
Frequently asked questions
What is Neurocrine Biosciences Inc's revenue?
Neurocrine Biosciences Inc's trailing twelve-month revenue is $3.10B, and consensus projects about $7.05B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is NBIX?
In its most recent fiscal year, NBIX ran a gross margin of 98.18%, an operating margin of 21.64%, and a net margin of 16.73%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does NBIX generate?
NBIX produced $748.70M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is NBIX's balance sheet healthy?
NBIX holds $713.00M in cash and equivalents against — in long-term debt, on $3.25B of shareholder equity. That debt is best read against the cash flow the business throws off each year.